Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; Institute for Respiratory Health, Perth, Australia.
School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Australia.
J Thorac Oncol. 2016 Apr;11(4):573-82. doi: 10.1016/j.jtho.2015.12.108. Epub 2016 Jan 8.
Malignant pleural mesothelioma (MPM) is a rare cancer with a heterogeneous prognosis. Prognostic models are not widely utilized clinically. Classification and regression tree (CART) analysis examines the interaction of multiple variables with a given outcome.
Between 2005 and 2014, all cases with pathologically confirmed MPM had routinely available histological, clinical, and laboratory characteristics recorded. Classification and regression tree analysis was performed using 29 variables with 18-month survival as the dependent variable. Risk groups were refined according to survival and clinical characteristics. The model was then tested on an external international cohort.
A total of 482 cases were included in the derivation cohort; the median survival was 12.6 months, and the median age was 69 years. The model defined four risk groups with clear survival differences (p < 0.0001). The strongest predictive variable was the presence of weight loss. The group with the best survival at 18 months (86.7% alive, median survival 34.0 months, termed risk group 1) had no weight loss, a hemoglobin level greater than 153 g/L, and a serum albumin level greater than 43 g/L. The group with the worst survival (0% alive, median survival 7.5 months, termed risk group 4d) had weight loss, a performance score of 0 or 1, and sarcomatoid histological characteristics. The C-statistic for the model was 0.761, and the sensitivity was 94.5%. Validation on 174 external cases confirmed the model's ability to discriminate between risk groups in an alternative data set with fair performance (C-statistic 0.68).
We have developed and validated a simple, clinically relevant model to reliably discriminate patients at high and lower risk of death using routinely available variables from the time of diagnosis in unselected populations of patients with MPM.
恶性胸膜间皮瘤(MPM)是一种罕见的癌症,其预后存在异质性。目前尚未广泛应用于临床的预后模型。分类回归树(CART)分析检查了多种变量与特定结果的相互作用。
在 2005 年至 2014 年期间,所有经病理证实的 MPM 病例均记录了常规的组织学、临床和实验室特征。采用 29 个变量,以 18 个月生存率为因变量进行分类回归树分析。根据生存和临床特征对风险组进行细化。然后在一个国际外部队列中测试该模型。
共纳入 482 例患者作为推导队列,中位生存期为 12.6 个月,中位年龄为 69 岁。该模型定义了四个具有明显生存差异的风险组(p < 0.0001)。最强的预测变量是体重减轻。在 18 个月时生存最佳的一组(86.7%存活,中位生存时间 34.0 个月,称为风险组 1)无体重减轻,血红蛋白水平大于 153g/L,血清白蛋白水平大于 43g/L。生存最差的一组(0%存活,中位生存时间 7.5 个月,称为风险组 4d)有体重减轻、体能状态评分 0 或 1 分,以及肉瘤样组织学特征。该模型的 C 统计量为 0.761,灵敏度为 94.5%。对 174 例外部病例的验证证实,该模型在另一个数据集中具有区分风险组的能力,表现良好(C 统计量为 0.68)。
我们开发并验证了一种简单的、具有临床相关性的模型,该模型能够使用未经选择的 MPM 患者人群在诊断时常规获得的变量,可靠地区分高死亡风险和低死亡风险的患者。